{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "Coagulation system",
      "Kallikrein-kinin system",
      "Kinins",
      "Renin-angiotensin system"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33065209",
  "DateCompleted": {
    "Year": "2021",
    "Month": "01",
    "Day": "29"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "11",
    "Day": "12"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2020",
        "Month": "10",
        "Day": "14"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.peptides.2020.170428",
      "S0196-9781(20)30177-7"
    ],
    "Journal": {
      "ISSN": "1873-5169",
      "JournalIssue": {
        "Volume": "135",
        "PubDate": {
          "Year": "2021",
          "Month": "Jan"
        }
      },
      "Title": "Peptides",
      "ISOAbbreviation": "Peptides"
    },
    "ArticleTitle": "The role of kallikrein-kinin and renin-angiotensin systems in COVID-19 infection.",
    "Pagination": {
      "StartPage": "170428",
      "MedlinePgn": "170428"
    },
    "Abstract": {
      "AbstractText": [
        "In November 2019 the first cases of a novel acute respiratory syndrome has been reported in Wuhan province, China. Soon after, in January 2020 the World Health Organization declared a pandemic state due to the dissemination of a virus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the cause of coronavirus disease 2019 (COVID-19). Being an unknown disease, it is essential to assess not only its main characteristic features and overall clinical symptomatology but also its patient infection mode and propagation to design appropriate clinical interventions and treatments. In this review the pathophysiology of SARS-CoV-2 infection and how the virus enters the cells and activates the immune system are described. The role of three systems involved in the SARS- CoV-2 infection (renin-angiotensin, kinin and coagulation systems) is discussed with the objectives to identify and try to explain several of the events observed during the evolution of the disease and to suggest possible targets for therapeutic interventions."
      ],
      "CopyrightInformation": "Copyright \u00a9 2020. Published by Elsevier Inc."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Universidade Federal do Rio de Janeiro, Instituto de Ci\u00eancias Biom\u00e9dicas, Laborat\u00f3rio de Farmacologia da Dor e da Inflama\u00e7\u00e3o, Rio de Janeiro, Brazil."
          }
        ],
        "LastName": "Carvalho",
        "ForeName": "Patricia Ribeiro de",
        "Initials": "PR"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Laval University, Quebec, Canada."
          }
        ],
        "LastName": "Sirois",
        "ForeName": "Pierre",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Universidade Federal do Rio de Janeiro, Instituto de Ci\u00eancias Biom\u00e9dicas, Laborat\u00f3rio de Farmacologia da Dor e da Inflama\u00e7\u00e3o, Rio de Janeiro, Brazil. Electronic address: patricia.dias@icb.ufrj.br."
          }
        ],
        "LastName": "Fernandes",
        "ForeName": "Patricia Dias",
        "Initials": "PD"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Peptides",
    "NlmUniqueID": "8008690",
    "ISSNLinking": "0196-9781"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Kinins"
    },
    {
      "RegistryNumber": "EC 3.4.21.-",
      "NameOfSubstance": "Kallikreins"
    },
    {
      "RegistryNumber": "EC 3.4.23.15",
      "NameOfSubstance": "Renin"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "immunology",
        "metabolism",
        "physiopathology",
        "transmission"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Repositioning"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Host-Pathogen Interactions"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Kallikreins"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Kinins"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Renin"
    },
    {
      "QualifierName": [
        "physiology"
      ],
      "DescriptorName": "Renin-Angiotensin System"
    },
    {
      "QualifierName": [
        "genetics",
        "pathogenicity"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Virus Internalization"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ]
}